Cost-effectiveness Declines As HPV Vaccination Age Increases
This article was originally published in The Pink Sheet Daily
Executive Summary
Harvard model finds cost-effectiveness depends on duration of immunity, benefits beyond preventing cervical cancer.
You may also be interested in...
Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest
Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.
Merck Plans Gardasil Campaign Targeting “Mid-adult” Women
FDA clears Pennsylvania manufacturing plant; vaccine sBLAs, including one for Gardasil in “older” women, can proceed.